The   announced Friday it will convene a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizers antismoking drug Chantix The agency will gather a panel of psychiatric drug experts to discuss the pills risks and how to best manage them Since  Chantix has carried the governments strongest safety warning  a black box label  because it may cause hostility agitation depression and suicidal thoughts The warning was added after the FDA received dozens of reports of suicide and hundreds of reports of suicidal behavior among patients taking the smokingcessation drug The drugs labeling tells patients to stop taking Chantix immediately if they experience agitation depressed mood suicidal thinking and other behavioral changes Doctors are advised to weigh the drugs risks against its potential benefits in helping patients quit smoking A spokeswoman for Pfizer said Friday that the company recently submitted new data to the FDA comparing the drugs psychiatric safety to placebo and other antismoking techniques Just this week FDA said it would   and was encouraging research into whether they might help smokers kick the habit